Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? the D-Vex Pilot Study
Key facts
- Who runs it
- Murdoch Childrens Research Institute
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 13 people enrolled
- Started
- 16 Oct 2017
- Ended
- 30 Jan 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Stoss vitamin D
- Daily vitamin D
- Stoss placebo
- Daily placebo
- Record updated
- 14 March 2025
- Why it stopped
- Recruitment very slow \& ongoing funding not obtained.
Who can take part
- Age
- 1 year to 12 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- moderate to severe atopic dermatitis with a SCORAD ≥ 20 at baseline
- aged between 1 ≤ 12 years of age at the time of randomisation
- regularly ingest the recommended dietary intake (RDI) of calcium and plan to do so for the next 3 months
- have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf
Who cannot take part
- use of vitamin D supplementation, including a stoss dose of vitamin D in the previous year, or daily supplementation in the past month
- received oral steroids within the past 6 months
- received oral immunosuppression in the past (cyclosporine, azathioprine, methotrexate)
- received UV therapy in the past 12 months
- receiving thiazide-type diuretics or anticonvulsant therapy
- ave renal or liver or gastrointestinal (e.g.: coeliac, inflammatory bowel disease) disease
- have ever been diagnosed with Hypercalcaemia, Hypertension or Rickets
- drink vitamin D fortified formula (all formulas) as the main milk intake
- have been fully formula fed within the past 6 months
- unable to provide consent without the aid of an interpreter
- in the opinion of the Investigator, are unable to follow the protocol
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Vitamin D is known to have a regulatory influence on both the immune system and skin barrier function. Studies in paediatric populations have found an inverse association of vitamin D levels and with both prevalence and severity of atopic dermatitis (AD). Trials of vitamin D as a treatment for AD are limited in number and size. There has never been a placebo-controlled randomised controlled trial of stoss high dose versus daily standard dose for the treatment of AD. Further, no trials have explored the presence of vitamin D pathway genes and response to treatment of AD. This pilot study will be used as a reference to determine outcomes and feasibility for undertaking a larger and more in depth definitive study.
The 3 groups in the trial
- Stoss vitamin DExisting treatment, for comparison
Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
Treatment: Stoss vitamin D and Daily placebo
- Daily vitamin DExisting treatment, for comparison
Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
Treatment: Daily vitamin D and Stoss placebo
- PlaceboPlacebo, for comparison
Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
Treatment: Stoss placebo and Daily placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study
- Record updated
- 14 March 2025